Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 23.08 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $35.00 thousand which missed the analyst consensus estimate of $50.00 thousand by 30.00 percent. This is a 85.04 percent decrease over sales of $234.00 thousand the same period last year.
Tesla’s Q1 US Sales Mainly Held Back By Very Model That Saved It From Bankruptcy Years Ago
As per the research company, Tesla sold 140,187 electric vehicles in the U.S. last quarter, marking a 13.3% drop from the 161,630 vehicles sold in the corresponding quarter of 2023.
